Diffuse sclerosing osteomyelitis: a case series and literature review

Matharu, J.; Taylor, Helena M.; Sproat, Chris; Kwok, Jerry; Brown, Joshua R.; Patel, Vinod

doi:10.1016/j.oooo.2019.11.010

Cited by 20 publications

(21 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The latter is a rare, non-suppurative form which is then subcategorised further. 7 Depending on the intensity of the infection and the host response, the clinical presentation and course of SCO may vary significantly. Fistula formation with purulent discharge and a segment of exposed, poorly vascularised bone may arise.…”

Section: Discussionmentioning

confidence: 99%

“…The Zurich classification 2 remains the most commonly used and describes three main types of osteomyelitis; AO, SCO and primary chronic osteomyelitis (PCO). The latter is a rare, non‐suppurative form which is then sub‐categorised further 7 …”

Section: Discussionmentioning

confidence: 99%

“…Primary chronic osteomyelitis is a non‐suppurative variant of unknown aetiology characterised by the absence of pus or fistula formation 12 . Diffuse sclerosing osteomyelitis, a challenging subtype of PCO has been shown to respond to bone modifying agents including bisphosphonates, 7,13‐19 which are synthetic analogues of naturally occurring pyro‐phosphate. The high affinity of bisphosphonates for calcium ions means that they attach to hydroxyapatite binding sites on the bone surface, especially in locations undergoing active resorption 20 .…”

Section: Discussionmentioning

confidence: 99%

“…The suggestion to use AA was justified based on its ability to reduce bone loss and its successful use in diffuse sclerosing osteomyelitis (DSO). 7 It was decided that surgery should be avoided until necessary, due to the extent of the area affected. Following commencement of AA, the patient reported rapid improvement of symptoms of pain and swelling with no further episodes of infection after 8 weeks, and a significant improvement in routine oral function.…”

Section: Case Reportmentioning

confidence: 99%

“…With this being the default option, it was agreed to trial the use of alendronic acid (AA) 70 mg once weekly in conjunction with oxytetracycline 500 mg QDS. The suggestion to use AA was justified based on its ability to reduce bone loss and its successful use in diffuse sclerosing osteomyelitis (DSO) 7 . It was decided that surgery should be avoided until necessary, due to the extent of the area affected.…”

Section: Case Reportmentioning

confidence: 99%

See 4 more Smart Citations

Secondary chronic osteomyelitis of the mandible: A resistant disease successfully treated with bisphosphonate therapy

et al. 2020

Self Cite

View full text Add to dashboard Cite

Management of secondary chronic osteomyelitis (SCO) of the mandible is complex and challenging condition. Antibiotics are often first line treatment but have difficulty penetrating the infected bone and surgical intervention can be extensive, disfiguring and may not provide cure. With increasing reports of successful management of primary chronic osteomyelitis with bisphosphonate therapy, it was considered a viable last line trial medication in a refractory SCO patient for whom surgery was not appropriate. The current case is the first in the literature to report successful management of SCO with oral bisphosphonates.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%